Bioequivalence Study of Two Olopatadine Hydrochloride Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions [0.03%]
奥洛他定 hydrochloride片在空腹及餐后条件下与参比制剂生物等效性研究-健康受试者中的一项随机、开放、两周期交叉试验
Yuyan Lei,Fang Pei,Qingqi Wu et al.
Yuyan Lei et al.
Olopatadine hydrochloride, a second-generation selective histamine H1 receptor antagonist, is an effective anti-allergic agent. This study evaluated the pharmacokinetics and bioequivalence of two olopatadine hydrochloride tablet formulation...
Comparative Bioequivalence and Safety Evaluation of Ibuprofen/Phenylephrine Hydrochloride Fixed-Dose Combination Tablets in Healthy Chinese Volunteers [0.03%]
对乙酰氨基酚/盐酸伪麻黄碱固定剂量复方 tablets在健康受试者中的生物等效性和安全性评价
Menghan Ye,Rui Zhang,Jing Wan et al.
Menghan Ye et al.
This single-center, randomized, open-label bioequivalence program compared two fixed-dose combination (FDC) tablets containing ibuprofen (200 mg) and phenylephrine hydrochloride (10 mg) from different manufacturers in healthy Chinese adults...
Integrating Pharmacogenomic Insights in GLP-1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management [0.03%]
GLP-1受体激动剂治疗中的药理基因组学见解整合：GLP1R和ARRB1变异体及CYP2D6的个性化肥胖管理的间接影响
Navodi Sandamini Jayathilaka,Arunodya Vishwanthi Weththasinghe,Nila Ganamurali et al.
Navodi Sandamini Jayathilaka et al.
Glucagon-like peptide-1 (GLP-1) receptor agonists have become frontline agents in obesity treatment due to their efficacy. However, there is considerable inter-individual variability in treatment response. Although these agents are primaril...
Amalia M Issa,Michael Fossler,Vijay V Upreti
Amalia M Issa
Clinical assessment of mocravimod as a victim of drug-drug interactions via CYP3A4 metabolism and transporters [0.03%]
莫考韦莫德临床评估：通过CYP3A4代谢和转运蛋白的药物相互作用受害者效应分析
Dymphy R Huntjens,Stephan Oehen,Elisabeth Kueenburg
Dymphy R Huntjens
Mocravimod, a novel immunomodulator targeting sphingosine-1-phosphate receptor (S1PR), is being developed as a maintenance treatment for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Preclini...
Correction to "Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsenin Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses" [0.03%]
“乙肝病毒转基因小鼠和健康志愿者的反义寡核苷酸倍比妥韦森药物的前期及一期评估：单次和多次给药的安全性、耐受性和药代动力学的临床剂量选择支持”一文的勘误
Published Erratum
Clinical pharmacology in drug development. 2025 Oct 27. DOI:10.1002/cpdd.1620 2025
Pharmacokinetics and bioequivalence of two N-acetylcysteine tablets in healthy Chinese volunteers under fasting and fed conditions [0.03%]
两种N-乙酰半胱氨酸片剂在健康中国受试者空腹及餐后条件下的药代动力学及生物等效性研究
Xianmiao Yin,Rui Xia,Huan Song et al.
Xianmiao Yin et al.
N-acetylcysteine (NAC) is a derivative of cysteine with potent mucolytic and antioxidant properties. However, the pharmacokinetics of NAC tablets remain unclear in healthy Chinese subjects. This study aimed to assess the pharmacokinetics, b...
Evaluation of clinical cardiac safety of zilurgisertib, an activin receptor-like kinase-2 (ALK2) inhibitor, in healthy participants [0.03%]
西鲁吉塞替布（活化素受体样激酶-2抑制剂）临床心脏安全性评价的健康受试者研究
Yan-Ou Yang,Hong Yang,Xing Liu et al.
Yan-Ou Yang et al.
The oral, small molecule inhibitor of activin receptor-like kinase-2, zilurgisertib (INCB000928), is under evaluation in fibrodysplasia ossificans progressiva. Cardiac safety was assessed using electrocardiogram (ECG) parameters and a plasm...
Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants [0.03%]
健康参与者中艾斯西明与阿托伐他汀药代动力学药物相互作用的评估
Matthias Hoch,Wendy Weis,Felix Huth et al.
Matthias Hoch et al.
Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two-treatment-period, drug-drug interaction study evaluated the effect of steady-...